{"schema":"pith.reference-change-event.v1","doi":"10.1016/j.clbc.2011.03.005","canonical_url":"https://pith.science/event/10.1016/j.clbc.2011.03.005","json_url":"https://pith.science/event/10.1016/j.clbc.2011.03.005.json","not_a_judgment":"This page records that a citing paper's bibliography includes a work with a published notice. It is not a judgment on the citing paper.","primary":{"event_id":395558,"doi":"10.1016/j.clbc.2011.03.005","event_type":"correction","event_type_label":"Correction","source":"crossref","source_label":"Crossref","event_date":"2011-08-03","title":"Erratum","work_title":"Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial","work_doi":"10.1016/j.clbc.2011.03.005","work_arxiv_id":null,"notice_doi":"10.1016/j.clbc.2011.06.004","flag_count":0,"flags_open":0,"flags_disputed":0,"latest_flag_at":null,"human_href":"/event/10.1016/j.clbc.2011.03.005","json_href":"/event/10.1016/j.clbc.2011.03.005.json"},"events":[{"event_id":395558,"doi":"10.1016/j.clbc.2011.03.005","event_type":"correction","event_type_label":"Correction","source":"crossref","source_label":"Crossref","event_date":"2011-08-03","title":"Erratum","work_title":"Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial","work_doi":"10.1016/j.clbc.2011.03.005","work_arxiv_id":null,"notice_doi":"10.1016/j.clbc.2011.06.004","flag_count":0,"flags_open":0,"flags_disputed":0,"latest_flag_at":null,"human_href":"/event/10.1016/j.clbc.2011.03.005","json_href":"/event/10.1016/j.clbc.2011.03.005.json"}],"flags":[{"id":9648,"status":"open","status_label":"Open","citing_arxiv_id":"2501.08744","citing_title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","ref_index":9,"evidence_raw":"for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719- 1725. 20130408. DOI: 10.1200/jco.2012.44.7912. 50. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92. 20110411. DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or 26 metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-376. 20110321. DOI: 10.1016/s1470-2045(11)70037-7.","evidence_cleaned":"for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719- 1725. 20130408. DOI: 10.1200/jco.2012.44.7912. 50. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92. 20110411. DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or 26 metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-376. 20110321. DOI: 10.1016/s1470-2045(11)70037-7","evidence_source_label":"citation context","event_type":"correction","event_type_label":"Correction","source_label":"Crossref","event_date":"2011-08-03","work_title":"Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial","work_doi":"10.1016/j.clbc.2011.03.005","event_doi":"10.1016/j.clbc.2011.03.005","flag_href":"/flags/9648","event_href":"/event/10.1016/j.clbc.2011.03.005","paper_href":"/paper/2501.08744","created_at":"2026-08-11T06:34:47.152789Z","dispute_note":null,"disputed_at":null,"disputed_by":null}],"flag_count":1,"flags_open":1,"flags_disputed":0,"desk_url":"https://pith.science/flags"}